The Chinese COVID Vaccines Don’t Seem to Work

Scores of Indonesian healthcare professionals showed symptoms for COVID-19 last week after being properly immunized with the Sinovac vaccine. As a result, Singaporean health officials have openly raised their concerns about a significant danger associated with Chinese vaccines.

Singapore is the most recent country to express reservations about the vaccine.

It Doesn’t Seem to Work

Last week, it was reported that dozens of the more than 350 doctors and health workers in Indonesia (who were infected with COVID-19, despite receiving the Sinovac vaccine) had been hospitalized; this cast further skepticism on the vaccine’s efficacy, particularly against more contagious variations of the virus.

A big number of Indonesians have received China’s vaccination, which was purchased and administered by the country.

In reaction to information from Indonesia (regarding indications of a considerable risk of vaccination breakthrough involving the Sinovac vaccine CoronaVac), Singapore’s Ministry of Health (MOH) director of medical services Kenneth Mak held a virtual press conference on June 15.

Singapore has already licensed Pfizer and Moderna vaccinations for its national immunization program, but private hospitals are allowed to provide Sinovac.

Singapore has high hopes for the Pfizer-BioNTech and Moderna immunizations, according to Mak. Upwards of 4.7 million doses have already been given to the country’s citizens so far. He did caution out, though, that the efficiency of various vaccines will vary greatly.

He stated that several countries that formerly relied on China’s immunizations to protect their citizens are now providing booster injections.

During early June, Bahrain, as well as the United Arab Emirates, began offering Pfizer vaccinations as boosters to patients who previously received Sinovac and Sinopharm vaccines from China.

Besides being given millions of China’s vaccinations doses to its people ever since the close of last year, the groups have significantly observed a big increase in COVID-19 cases.

30% of Chinese Vaccine Recipients Have no Antibodies

Meanwhile, a clinical investigation in Serbia found that after receiving the Sinopharm vaccination, 30% of the elderly aged 65 and up had no antibodies. Serbia is the very first Eu nation to receive immunizations from China.

The Sinovac and Sinopharm vaccines have been approved for emergency use by the World Health Organization (WHO). China’s immunizations have shown efficacy rates of 50 to 84 percent in phase 3 clinical trials around the world.

Chinese businesses, on the other hand, have yet to make their Phase 3 trial data public. Concerns have also been raised about the lack of transparency around vaccine trials.

The Hong Kong department has signed a safety review report on COVID-19 vaccines, according to Hong Kong public broadcasting station RTHK. Aside from the scores of deaths, the report revealed that there were 87 occurrences of face immobility linked to immunizations in Hong Kong through May.

The Sinovac vaccine was given to half of the patients, while the Chinese BioNTech vaccine was given to the other half. BioNTech, the co-developer of the Pfizer BioNTech vaccine, has inked a deal with Shanghai Fosun Pharmaceuticals Co., allowing it to make and distribute COVID-19 vaccines exclusively for China, Hong Kong, Macau, and Taiwan by utilizing BioNTech’s mRNA technique.